Oversikt over tumorrettede intervensjonsstudier i Norge åpne for inklusjon – Klikk her
Intraoperativ strålebehandling av brystkreftpasienter
En kvalitetssikringsstudie (etter Targit studien). PI: Steinar Lundgren.
OPTIMA
OPTIMA (EMIT2). Optimal Personalised Treatment of early breast cancer using Multi-parameter Analysis. Bruk av Prosigna test til adjuvant behandlingsbeslutning. PI: Bjørn Naume.
AXSANA
AXillary Surgery After NeoAdjuvant treatment (PI: Ellen Schlichting)
NEOLETRIB
Neoadjuvant Treatment of Locally-advanced Breast Cancer Patients With Ribociclib and Letrozole (PI: Jürgen Geiser)
NAPEER
NeoAdjuvant PErsonalized therapy in Estrogen Receptor positive breast cancer (NAPEER). An open label phase II trial of endocrine treatment with or without capivasertib, followed by response assessment before neoadjuvant chemotherapy with bevacizumab (if ViRP signature positive).(PI: Olav Engebråten)
TAORMINA
Treatment of Oligometastatic breast cancer – a randomized phase-3 trial comparing stereotactic ablative radiotherapy and systemic treatment with systemic treatment alone as 1. line treatment (PI: Vidar Flote)
T-REX
Tailored regional external beam radiotherapy in clinically node-negative breast cancer patients with 1-2 sentinel node macrometastases; an open, multicenter, randomized non-inferiority phase 3-trial (PI: Ingvil Mjaaland)
SERENA-6
A Phase III, Double-blind, Randomised Study to Assess Switching to AZD9833 (a Next Generation, Oral SERD) + CDK4/6 Inhibitors (Palbociclib or Abemaciclib) vs Continuing NSAI + CDK4/6 Inhibitors in HR+/HER2- MBC Patients with Detectable ESR1 Mutation Without Clinical or Radiological Progression During 1L Treatment with NSAI + CDK4/6 Inhibitor A ctDNA Guided Early Switch Study (PI: Alina Porojnicu)
NBCG 